What is the global market size of Plasma Therapy Market?

Global Plasma Therapy Market size was valued at USD 297.6 million in 2021 and is poised to grow from USD 339.26 million in 2022 to USD 967.78 million by 2030, growing at a CAGR of 14% in the forecast period (2023-2030).

Plasma Therapy Companies

Plasma Therapy Market Competitive Landscape

Global plasma therapy market's competitive landscape provides information by competitors. An overview of the company, financials, revenue, market potential, R&D investments, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launches, product breadth and depth, and application dominance are among the data that are included. Only the market emphasis on plasma therapy that the companies have is covered by the data points given above.

Plasma Therapy Market Top Player’s Company Profiles

Biotest AG
CSL Behring
Grifols S.A.
Kedrion S.p.A.
Octapharma AG
Takeda Pharmaceutical Company Limited
Zimmer Biomet
Baxter International Inc.
China Biologic Products Holdings, Inc.
GC Pharma
Green Cross Corp.
Japan Blood Products Organization
LFB SA
Shanghai RAAS Blood Products Co., Ltd.
China National Biotec Group Co., Ltd. (CNBG)
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Jiangxi Boya Bio-Pharmaceutical Co., Ltd.
Bio Products Laboratory Ltd. (BPL)
BioLife Plasma Services
Canadian Plasma Resources

Plasma Therapy Market

FAQs

Plasma Therapy Market size was valued at USD 297.6 million in 2019 and is poised to grow from USD 339.26 million in 2023 to USD 967.78 million by 2031, growing at a CAGR of 14% in the forecast period (2024-2031).

plasma therapy market's competitive landscape provides information by competitors. An overview of the company, financials, revenue, market potential, R&D investments, new market initiatives, presence, production sites and facilities, production capacities, company strengths and weaknesses, product launches, product breadth and depth, and application dominance are among the data that are included. Only the market emphasis on plasma therapy that the companies have is covered by the data points given above. 'Biotest AG', 'CSL Behring', 'Grifols S.A.', 'Kedrion S.p.A.', 'Octapharma AG', 'Takeda Pharmaceutical Company Limited', 'Zimmer Biomet', 'Baxter International Inc.', 'China Biologic Products Holdings, Inc.', 'GC Pharma', 'Green Cross Corp.', 'Japan Blood Products Organization', 'LFB SA', 'Shanghai RAAS Blood Products Co., Ltd.', 'China National Biotec Group Co., Ltd. (CNBG)', 'Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.', 'Jiangxi Boya Bio-Pharmaceutical Co., Ltd.', 'Bio Products Laboratory Ltd. (BPL)', 'BioLife Plasma Services', 'Canadian Plasma Resources'

The utilization of platelet-rich plasma is increasing as a result of increasing sports injury rates and an increase in cosmetic surgery, as well as growing participation in sporting activities. The rise of the industry is also driven by a increase in the use of platelet rich plasma (PRP) in research.

The rise in patients with androgenic alopecia and orthopedic disorders may present additional potential growth opportunities for the plasma therapy market in the coming years. However, the limited use of PRP in diabetic patients and kidney problems may pose further challenges to the growth of the market in the near future. The healthcare company's access to trying to cut treatment options - The number of available treatments has considerably risen as a result of the healthcare industry's continued advancement. This has aided the consumers in choosing a treatment choice that is appropriate for their level of disposable income. Numerous services offered by both the public and private sectors have also assisted the healthcare industry in improving its success rate, even with relation to rare disorders. The success rate for treating rare diseases has increased as a result of the faster progress being made in the field of healthcare technology and tools.

Due to the existence of top platelet-rich plasma therapy product manufacturers, active involvement of academic and research institutions in trying to cut research and development activities, rising public awareness of the benefits of platelet-rich plasma therapies, and support from regulatory bodies and the government to promote the use of PRP for medical purposes, North America held the largest market share for plasma therapy in 2021. The availability of highly skilled individuals and the region's well-developed healthcare infrastructure both drive market growth.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Plasma Therapy Market Competitive Landscape

Plasma Therapy Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

Plasma Therapy Market Competitive Landscape

Plasma Therapy Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Plasma Therapy Market?

Who are the key vendors in the Plasma Therapy Market?

What is the key driver of Plasma Therapy Market?

What is the key market trend for Plasma Therapy Market?

Which region accounted for the largest share in Plasma Therapy Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300